These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 19895269)

  • 21. Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin.
    Eke I; Sandfort V; Mischkus A; Baumann M; Cordes N
    Radiother Oncol; 2006 Aug; 80(2):178-84. PubMed ID: 16891020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck.
    Younes MN; Yigitbasi OG; Yazici YD; Jasser SA; Bucana CD; El-Naggar AK; Mills GB; Myers JN
    Arch Otolaryngol Head Neck Surg; 2007 Jan; 133(1):15-23. PubMed ID: 17224516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced chondrocyte proliferation and chondrodysplasia in mice lacking the integrin-linked kinase in chondrocytes.
    Terpstra L; Prud'homme J; Arabian A; Takeda S; Karsenty G; Dedhar S; St-Arnaud R
    J Cell Biol; 2003 Jul; 162(1):139-48. PubMed ID: 12835312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PINCH-1 promotes tubular epithelial-to-mesenchymal transition by interacting with integrin-linked kinase.
    Li Y; Dai C; Wu C; Liu Y
    J Am Soc Nephrol; 2007 Sep; 18(9):2534-43. PubMed ID: 17656471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrin-linked kinase is dispensable for multiple myeloma cell survival.
    Steinbrunn T; Siegmund D; Andrulis M; Grella E; Kortüm M; Einsele H; Wajant H; Bargou RC; Stühmer T
    Leuk Res; 2012 Sep; 36(9):1165-71. PubMed ID: 22658851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrin-linked kinase: a possible role in scar contracture.
    Levinson H; Turner CE; Ehrlich HP
    Ann Plast Surg; 2004 Feb; 52(2):204-11. PubMed ID: 14745274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrin-linked kinase regulates senescence in an Rb-dependent manner in cancer cell lines.
    Duminuco R; Noble JW; Goody J; Sharma M; Ksander BR; Roskelley CD; Cox ME; Mills J
    Cell Cycle; 2015; 14(18):2924-37. PubMed ID: 26176204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to radio- and chemotherapy and the tumour microenvironment.
    Barcellos-Hoff MH; Cordes N
    Int J Radiat Biol; 2009 Nov; 85(11):920-2. PubMed ID: 19895267
    [No Abstract]   [Full Text] [Related]  

  • 29. Binding mechanism of caffeic acid and simvastatin to the integrin linked kinase for therapeutic implications: a comparative docking and MD simulation studies.
    Gulzar M; Ali S; Khan FI; Khan P; Taneja P; Hassan MI
    J Biomol Struct Dyn; 2019 Oct; 37(16):4327-4337. PubMed ID: 30488773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrin-linked kinase 1: role in hormonal cancer progression.
    Cortez V; Nair BC; Chakravarty D; Vadlamudi RK
    Front Biosci (Schol Ed); 2011 Jan; 3(2):788-96. PubMed ID: 21196412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. beta1 integrin targeting to enhance radiation therapy.
    Nam JM; Chung Y; Hsu HC; Park CC
    Int J Radiat Biol; 2009 Nov; 85(11):923-8. PubMed ID: 19895268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrin-linked kinase (ILK) in combination molecular targeting.
    Edwards LA; Shabbits JA; Bally M; Dedhar S
    Cancer Treat Res; 2004; 119():59-75. PubMed ID: 15164873
    [No Abstract]   [Full Text] [Related]  

  • 33. Signalling pathways involved in clinical responses to chemotherapy.
    Perona R; Sánchez-Pérez I
    Clin Transl Oncol; 2007 Oct; 9(10):625-33. PubMed ID: 17974523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell signalling and radiation survival: the impact of protein phosphatases.
    Hamilton J; Bernhard EJ
    Int J Radiat Biol; 2009 Nov; 85(11):937-42. PubMed ID: 19895270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrin-linked kinase: a Scaffold protein unique among its ilk.
    Dagnino L
    J Cell Commun Signal; 2011 Jun; 5(2):81-3. PubMed ID: 21484187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p21-activated kinase 1: an emerging therapeutic target.
    Vadlamudi RK; Kumar R
    Cancer Treat Res; 2004; 119():77-88. PubMed ID: 15164874
    [No Abstract]   [Full Text] [Related]  

  • 37. Cancer cell resistance mechanisms: a mini review.
    Al-Dimassi S; Abou-Antoun T; El-Sibai M
    Clin Transl Oncol; 2014 Jun; 16(6):511-6. PubMed ID: 24647842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of integrin-linked kinase (ILK) in tumorigenesis and its potential implication as a biomarker and therapeutic target for human cancer.
    Zheng CC; Hu HF; Hong P; Zhang QH; Xu WW; He QY; Li B
    Am J Cancer Res; 2019; 9(1):186-197. PubMed ID: 30755822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OSU-T315 as an Interesting Lead Molecule for Novel B Cell-Specific Therapeutics.
    Van Belle K; Herman J; Waer M; Sprangers B; Louat T
    J Immunol Res; 2018; 2018():2505818. PubMed ID: 30276218
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.